Kura Oncology (NASDAQ:KURA) Earns “Market Outperform” Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $32.00 target price on the stock.

KURA has been the subject of a number of other reports. Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Wednesday, November 13th. UBS Group initiated coverage on shares of Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $10.80 on Tuesday. The firm has a 50 day moving average of $18.08 and a 200 day moving average of $19.76. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $839.85 million, a price-to-earnings ratio of -4.66 and a beta of 0.86. Kura Oncology has a 52 week low of $9.06 and a 52 week high of $24.17.

Institutional Trading of Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in Kura Oncology during the third quarter valued at $25,000. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 1st quarter valued at about $110,000. Point72 DIFC Ltd purchased a new position in shares of Kura Oncology in the 3rd quarter valued at about $146,000. Quarry LP acquired a new position in Kura Oncology in the 2nd quarter worth about $196,000. Finally, Erste Asset Management GmbH acquired a new position in Kura Oncology in the 3rd quarter worth about $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.